Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Interest Expenses (2016 - 2017)

Heron Therapeutics (HRTX) has disclosed Interest Expenses for 3 consecutive years, with $2.2 million as the latest value for Q4 2016.

  • For the quarter ending Q4 2016, Interest Expenses changed N/A year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Sep 2017, up 942.58%, and an annual FY2025 reading of $9.6 million, up 59.23% over the prior year.
  • Interest Expenses was $2.2 million for Q4 2016 at Heron Therapeutics, up from $209000.0 in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.2 million in Q4 2016 and bottomed at $71000.0 in Q1 2013.
  • Average Interest Expenses over 3 years is $573200.0, with a median of $205000.0 recorded in 2013.
  • Peak annual rise in Interest Expenses hit 64.85% in 2013, while the deepest fall reached 64.85% in 2013.
  • Year by year, Interest Expenses stood at $202000.0 in 2012, then increased by 3.47% to $209000.0 in 2013, then soared by 942.58% to $2.2 million in 2016.
  • Business Quant data shows Interest Expenses for HRTX at $2.2 million in Q4 2016, $209000.0 in Q3 2013, and $205000.0 in Q2 2013.